| 2022 | Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience | CANCER IMMUNOLOGY IMMUNOTHERAPY |
| 2022 | The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
| FRONTIERS IN ONCOLOGY |
| 2022 | Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC | CANCER DISCOVERY |
| 2022 | Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD) | CLINICAL LUNG CANCER |
| 2021 | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC | JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
| JTO Clinical and Research Reports |
| 2021 | Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer | LUNG CANCER |
| 2021 | The promise of bispecific antibodies: Clinical applications and challenges | CANCER TREATMENT REVIEWS |
| 2021 | Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study | LANCET |
| 2021 | Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
| CLINICAL CANCER RESEARCH |
| 2021 | Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
| CLINICAL CANCER RESEARCH |
| 2021 | Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2021 | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
| JTO Clinical and Research Reports |
| 2021 | A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
| CANCER MEDICINE |
| 2021 | Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)
| CLINICAL LUNG CANCER |
| 2021 | Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study | LANCET ONCOLOGY |
| 2021 | Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study
| CANCERS |
| 2021 | Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
| JTO Clinical and Research Reports |
| 2021 | Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
| CANCERS |
| 2021 | Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target? | JOURNAL OF THORACIC ONCOLOGY |
| 2021 | DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2021 | Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2021 | Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients
| SCIENTIFIC REPORTS |
| 2021 | Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
| ANNALS OF ONCOLOGY |
| 2020 | Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2020 | Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
| BRITISH JOURNAL OF CANCER |
| 2020 | Preface | Memo |
| 2020 | Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I | MOLECULAR CANCER THERAPEUTICS |
| 2020 | The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
| JOURNAL OF THORACIC DISEASE |
| 2020 | First-in-human safety, pharmacokinetics, and preliminary efficacy of
TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
| EUROPEAN JOURNAL OF CANCER |
| 2020 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma | CANCER |
| 2020 | Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
| CANCER RESEARCH AND TREATMENT |
| 2020 | A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy | ANNALS OF ONCOLOGY |
| 2020 | Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer | EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2020 | Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study
| LUNG CANCER |
| 2020 | Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC | CANCER DISCOVERY |
| 2020 | Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2020 | Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade | JCI INSIGHT |
| 2020 | Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
| CLINICAL CANCER RESEARCH |
| 2020 | Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2020 | Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial | ANNALS OF ONCOLOGY |
| 2020 | Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
| SCIENTIFIC REPORTS |
http://orcid.org/0000-0002-5562-270X
(7401747804)
